Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

(2020) Manli Wang et al.   CELL RESEARCH

Chloroquine and hydroxychloroquine as available weapons to fight COVID-19

(2020) Philippe Colson et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China

(2020) Dawei Wang et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus

(2020) Calvin J Gordon et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019

(2020) Wenzheng Han et al.   JOURNAL OF MEDICAL VIROLOGY

On the use of corticosteroids for 2019-nCoV pneumonia

(2020) Lianhan Shang et al.   LANCET

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

(2020) Peter Richardson et al.   LANCET

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

(2020) Nanshan Chen et al.   LANCET

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

(2020) Chaolin Huang et al.   LANCET

Convalescent plasma as a potential therapy for COVID-19

(2020) Long Chen et al.   LANCET INFECTIOUS DISEASES

Anti-HCV, nucleotide inhibitors, repurposing against COVID-19

(2020) Abdo A. Elfiky   LIFE SCIENCES

First Case of 2019 Novel Coronavirus in the United States

(2020) Michelle L. Holshue et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial

(2020) Yaseen M. Arabi et al.   Trials

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

(2020) Timothy P. Sheahan et al.   Nature Communications

Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential

(2020) Jimin Xu et al.   ACS Infectious Diseases

Of chloroquine and COVID-19

(2020) Franck Touret et al.   ANTIVIRAL RESEARCH

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

(2020) Xueting Yao et al.   CLINICAL INFECTIOUS DISEASES

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

(2020) Philippe Gautret et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

(2020) Fei Zhou et al.   LANCET

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

(2020) Bin Cao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

(2020) Jianjun Gao et al.   BioScience Trends

Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment

(2020) Zhenwei Wang et al.   BioScience Trends

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China

(2020) Chaomin Wu et al.   JAMA Internal Medicine

Efficacy and Safety of Nitazoxanide in Addition to Standard of Care for the Treatment of Severe Acute Respiratory Illness

(2019) Ana E Gamiño-Arroyo et al.   CLINICAL INFECTIOUS DISEASES

Ribavirin and Interferon Therapy for Critically Ill Patients with the Middle East Respiratory Syndrome: A multicenter observational study

(2019) Yaseen Arabi et al.   CLINICAL INFECTIOUS DISEASES

XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia

(2019) Yuanlin Song et al.   CRITICAL CARE MEDICINE

Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome

(2019) Chelsea Kotch et al.   Expert Review of Clinical Immunology

A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics

(2019) Sabue Mulangu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome

(2018) Yaseen M. Arabi et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes

(2018) Min-Han Lin et al.   ANTIVIRAL RESEARCH

Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells

(2018) Jae H Park et al.   CLINICAL INFECTIOUS DISEASES

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome

(2018) Robert Q. Le et al.   ONCOLOGIST

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease

(2018) Maria L. Agostini et al.   mBio

ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells

(2018) Daniel W Lee et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses

(2017) Dustin Siegel et al.   JOURNAL OF MEDICINAL CHEMISTRY

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

(2017) Timothy P. Sheahan et al.   Science Translational Medicine

Late Ebola virus relapse causing meningoencephalitis: a case report

(2016) Michael Jacobs et al.   LANCET

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

(2016) Travis K. Warren et al.   NATURE

Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus

(2016) Jean-François Rossignol   Journal of Infection and Public Health

Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset

(2015) Jasper Fuk-Woo Chan et al.   JOURNAL OF INFECTIOUS DISEASES

Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture

(2014) Adriaan H. de Wilde et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial

(2014) Jason Haffizulla et al.   LANCET INFECTIOUS DISEASES

Pharmacokinetics of Lopinavir/Ritonavir Crushed Versus Whole Tablets in Children

(2011) Brookie M. Best et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Broad-Spectrum In Vitro Activity and In Vivo Efficacy of the Antiviral Protein Griffithsin against Emerging Viruses of the Family Coronaviridae

(2009) B. R. O'Keefe et al.   JOURNAL OF VIROLOGY

A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication

(2008) K. Ratia et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA